Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.

from MarketWatch.com - Top Stories https://ift.tt/3uG64B4
via IFTTT
from MarketWatch.com - Top Stories https://ift.tt/3uG64B4
via IFTTT
Kommentare
Kommentar veröffentlichen